Levamisol Production Cost Reports

The report provides detailed analysis essential for establishing a levamisole production plant. It encompasses all critical aspects necessary for levamisole production, including the cost of levamisole production, levamisole plant cost, levamisole production costs, and the overall levamisole production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a levamisole production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Levamisole Market Analysis: Demand and Supply Analysis, and Sourcing

Levamisole is the active L-isomer of tetramisole, an imidazothiazole anthelmintic discovered at Janssen Pharmaceutica. It paralyzes nematode worms by acting as an agonist at their nicotinic acetylcholine receptors, which keeps their body muscles in constant contraction. The worms lose muscle control, stop feeding, and are expelled from the gut, airways, or lungs within a day or so. The D-isomer, dextramisole, adds toxicity but little worm-killing power, so the pure L-isomer replaced the racemate. Levamisole also has immunomodulating effects, which led to human uses in cancer, rheumatoid arthritis, and kidney disease. Today, veterinary medicine, especially cattle and sheep farming, is its main market by far.

Demand for levamisole comes mostly from livestock farming. Farmers use it against gut worms and lungworms in cattle, sheep, goats, pigs, and poultry, mostly in grazing systems with heavy worm challenge. Injections, oral drenches, pour-ons, boluses, and feed or water premixes are all common, depending on species and farm size. In the UK, Norbrook's Levacide injection gives 7.5 mg per kg of body weight to cattle and sheep by subcutaneous injection. Human use is small, scattered, and limited to a few countries. The US withdrew Ergamisol, a colon cancer adjuvant used with fluorouracil, in 2000 because of agranulocytosis, and Canada followed in 2003. Some countries still use levamisole for steroid-dependent nephrotic syndrome in children and for human worm infections.

Supply is concentrated in China, with smaller roles for India and Europe. Pharmaoffer lists Changzhou Pharmaceutical and Nanjing White Whale Pharmaceutical as producers holding CEPs. Changzhou Comwin Fine Chemicals is listed as a GMP producer, and Denmark's Chr. Olesen distributes Chinese material with a US DMF. A major supply risk is illicit diversion, since levamisole has become a common cocaine adulterant in North America, Europe, and Latin America. A levamisole demand and supply analysis has to weigh livestock numbers, anthelmintic resistance, Chinese capacity, diversion controls, and price competition from other wormers.

Summary of the Product, Grades, and Uses

Levamisole base has the molecular formula C11H12N2S, a molar mass of 204.29 g/mol, and the CAS number 14769-73-4. The drug substance is usually levamisole hydrochloride, C11H12N2S·HCl, with a molar mass of 240.75 g/mol and CAS 16595-80-5. Its chemical name is the S isomer of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole. The hydrochloride is a white to almost white crystalline powder that dissolves freely in water and in methanol, but only slightly in less polar solvents. Optical rotation in water is strongly negative, near -135 degree, which serves as a check of isomer purity. Racemic tetramisole hydrochloride is a separate, cheaper product with its own CAS number, still sold in some veterinary markets.

Levamisole is available in three grades, each serving different customers and having its own quality standards and documentation requirements. Veterinary grade accounts for the largest volume and is used to make injections, drenches, boluses, and premixes for farm and companion animals. Human pharmaceutical grade is made under GMP and meets European Pharmacopeia or similar standards. It is used by tablet manufacturers in markets where levamisole is still used in human medicine. Research and reference grades are supplied to quality control laboratories, forensic laboratories, and pharmacology research groups.

Each lot is tested for assay, specific optical rotation, related substances, dextramisole content, water, sulfated ash, and residual solvents. Heavy metals, clarity of solution, pH, and loss on drying are checked too. Veterinary products range from 1.5% to 7.5% injections and drenches up to concentrated premixes. Human tablets, where sold, usually contain 40 mg or 50 mg, and are often given as single or weekly doses. Packaging is usually 25 kg fiber drums with double polyethylene liners, labels, and tamper seals.

Main End-Uses of Levamisole

Veterinary deworming is the core end-use for levamisole in cattle, sheep, goats, pigs, poultry, and companion animals. It works against Trichostrongylus, Cooperia, Ostertagia, Haemonchus, Nematodirus, and lungworms. Farmers value its fast action, low cost, and use in rotation with benzimidazoles and macrocyclic lactones. Withdrawal periods in the UK label are 28 days for cattle meat and 15 days for sheep meat. The product is not authorized for cows, ewes, or goats producing milk for people. Combination drenches with other wormers are common in Australia and New Zealand. These products help slow the spread of resistance on sheep farms.

Human medicine is the second end-use for levamisole, in pediatric nephrology, tropical medicine, and some cancer and rheumatology settings. Pediatric nephrologists use it to reduce relapses and cut steroid exposure in children with steroid-dependent nephrotic syndrome. Some countries in Asia, Africa, and Latin America still use single doses for roundworm and hookworm infection. Its old roles in colon cancer, rheumatoid arthritis, and recurrent infections have faded. Human demand is small but steady where it remains approved, mostly through hospital and public health tenders.

Research, testing, and forensic work also contribute to demand for levamisole. Immunology laboratories use it to study its effects on T cells, macrophages, and neutrophils. Forensic and toxicology laboratories buy reference standards because levamisole is often used to cut cocaine. Hospital laboratories may also test for it in patients with unexplained vasculitis. Biochemistry laboratories use it to block alkaline phosphatase in staining, blotting, histology, and immunoassay tests. These customers order quantities ranging from milligrams to kilograms and often require strict documentation, chain-of-custody records, and certificates of analysis.

Levamisole Market Risks

Levamisole faces risks from drug resistance, regulations, safety concerns, and illegal use. Resistance to levamisole among worms has spread in sheep and goats in Australia, New Zealand, South Africa, South America, and parts of Europe. Newer and combination treatments, including monepantel, derquantel, ivermectin, and moxidectin, compete for the same market. Residue limits, withdrawal periods, and milk restrictions also limit its use in dairy animals. In humans, levamisole can cause serious side effects, including agranulocytosis, vasculitis, and skin damage, which led to the withdrawal of its US approval. Its use as an additive in cocaine has also increased checks on buyers and shipments. Some regulators and suppliers now verify large orders and may refuse unusual purchases.

Manufacturing risks arise from controlling chirality, handling reactive chemicals, managing sulfur compounds, and treating waste. The resolution step must keep dextramisole levels low and ensure consistent optical rotation and crystal size. Thionyl chloride and hydrogen chloride are corrosive and can release toxic gases. Styrene oxide is suspected of causing cancer, so it must be handled in closed systems with proper ventilation and protective equipment. Sulfur-containing waste can cause bad odors and corrode equipment, so it needs careful treatment. Batches may fail quality checks due to incorrect optical rotation, unwanted impurities, color changes, or leftover solvents. Most of these problems are linked to the resolution step.

Levamisole Production Process and Main Cost Drivers

The levamisole production process runs from styrene oxide and 2-aminothiazoline receipt through cyclization to racemic tetramisole, resolution with dibenzoyl-D-tartaric acid, salt formation, crystallization, drying, and packing, with recycling of the D isomer.

1. By Resolution of Racemic Tetramisole Made from Styrene Oxide and 2-Aminothiazoline: The main inputs are styrene oxide, 2-aminothiazoline or 2-iminothiazolidine, thionyl chloride, hydrochloric acid, sodium hydroxide, dibenzoyl-D-tartaric acid, potassium tert-butoxide, dimethylformamide, toluene, ethanol, acetone, and water.

Levamisole production starts with racemic tetramisole. In the most commonly described process, styrene oxide reacts with 2-aminothiazoline to form a hydroxy phenylethyl iminothiazolidine. Thionyl chloride then converts the alcohol group into a chloride. Heating the product in a suitable solvent forms the second ring, producing tetramisole hydrochloride, which is then filtered, washed, and dried. Other published methods use phenacyl bromide, 2-methoxyethylamine, potassium cyanate, and phosphorus pentasulfide. An American Cyanamid patent describes this method, which also includes palladium-based hydrogenation and ring closure using acid. The styrene oxide route has fewer steps, costs less, and is easier to use for large-scale production.

Resolution separates the two isomers, and it is the heart of the process. A Hungarian study describes mixing tetramisole hydrochloride with the disodium salt of dibenzoyl-D-tartaric acid in water. This aqueous method avoids large volumes of chlorinated solvent. The levamisole salt precipitates at once, giving about 67% to 74% of the available L isomer. About 96% of the resolving agent is recovered from the mother liquor. Older routes used d-camphorsulfonic acid in chloroform below -10 degree Celsius. Yields there reached no more than 80%. The D isomer is racemized with potassium tert-butoxide in dry dimethylformamide and returned to the resolution as racemate, at about 96% yield. Sodium hydroxide frees the levamisole base, which is converted to the hydrochloride and crystallized. Resolution yield, D isomer recycling, and resolving agent recovery set most of the conversion cost.

Main Factors Affecting Levamisole Production Cost

Levamisole production costs depend mainly on how efficiently the isomers are separated and the cost of the starting materials. In theory, producing 1 kg of levamisole hydrochloride requires about 0.50 kg of styrene oxide, 0.42 kg of 2-aminothiazoline, and 0.49 kg of thionyl chloride. Only half of each racemate batch is the required L isomer, so recycling the D isomer is important. Without recycling, racemate use could rise to about three times the theoretical amount. Effective conversion of the D isomer back into the racemate helps keep material use close to the theoretical requirement, plus normal processing losses. Dibenzoyl-D-tartaric acid is expensive, so recovering and reusing it, while reducing losses, helps lower production costs.

Other production costs come from solvents, energy, labor, and waste treatment. Dimethylformamide used in racemization and organic solvents used for extraction need to be recovered and reused. The thionyl chloride process requires scrubbers to remove sulfur dioxide and hydrogen chloride, along with caustic chemicals and regular monitoring. Labor is mainly needed for isomer separation, racemization, filtration, and crystallization. Quality checks cover assay, optical rotation, related substances, dextramisole content, water, and residual solvents. Low prices for veterinary APIs leave little room for losses caused by poor yields. Most plants produce several products to remain profitable.

Raw Materials for Levamisole Production Plant and its Procurement

Raw material sourcing for levamisole centers on styrene oxide, 2-aminothiazoline, thionyl chloride, and the resolving agent. Styrene oxide comes from styrene epoxidation plants, mainly in China, and travels in drums or isotanks under nitrogen. 2-Aminothiazoline is made from ethanolamine derivatives and thiocyanate or thiourea chemistry by Chinese fine chemical makers. Thionyl chloride is a bulk chemical from chlorination plants in China, India, Europe, and the US. Dibenzoyl-D-tartaric acid comes from tartaric acid and benzoyl chloride, made by resolving agent producers in China and India. Solvents, caustic soda, and hydrochloric acid are bought locally.

Raw material quality affects yield, optical purity, and product color. Styrene oxide must contain low levels of phenylacetaldehyde and polymer. 2-Aminothiazoline must have low levels of thiourea, water, and color. Dibenzoyl-D-tartaric acid must have high optical purity because the presence of its L form can affect isomer separation. Supply contracts set limits for assay, water content, color, and optical rotation. Prices usually follow Chinese market benchmarks. Each batch is sampled and tested before use. Suppliers are audited before approval, and any changes require fresh testing. Using two suppliers for styrene oxide and the resolving agent helps prevent production delays caused by shortages.

Sustainability and Regulatory Requirements

Levamisole production requires careful handling of harmful gases, sulfur-containing waste, solvents, and styrene oxide. The thionyl chloride process releases sulfur dioxide and hydrogen chloride, which are captured using caustic scrubbers and converted into sulfite, sulfate, and chloride salts. Sulfur-containing waste liquids need chemical or biological treatment to reduce bad odors and toxicity. Dimethylformamide, toluene, and alcohols must be recovered, dried, tested, and reused. Recovering the resolving agent helps reduce waste and costs. Many plants also reuse treated process water. Styrene oxide must be stored in closed systems at low temperatures, with nitrogen blanketing and controls to prevent vapor leaks.

Regulatory requirements for levamisole depend on its use in veterinary medicine, human medicine, and forensic testing. Veterinary products need marketing approval supported by residue data, maximum residue limits, and withdrawal periods. API manufacturers submit Certificates of Suitability (CEPs) for European markets, Drug Master Files (DMFs) where required, and local registrations in Asia, Africa, and Latin America. Manufacturing plants must follow good manufacturing practices (GMP), with ICH Q7 serving as the main reference for API production. Human products have been withdrawn in the US, so supply there mainly serves animal health and research needs. Due to the risk of illegal use, companies must check customers, maintain shipment records, and store the product securely. Animal product labels warn against use with organophosphates within 14 days.

CAPEX and OPEX for a Levamisole Production Plant

A levamisole plant is a multi-purpose API facility with corrosion-resistant reactors, equipment for isomer separation and racemization, and solvent recovery systems. The plant setup cost includes glass-lined reactors for ring opening, chlorination, and ring formation. Scrubbers remove sulfur dioxide and hydrogen chloride released during the thionyl chloride process, while backup fans and alarms provide added safety. Isomer separation requires crystallizers, centrifuges, and tanks to recover the resolving agent. Racemization requires dry reactors under nitrogen and vacuum systems to recover dimethylformamide. Dryers, mills, sifters, and blenders are used to finish the API. Utilities include steam, chilled brine, nitrogen, vacuum, and wastewater treatment. The quality control laboratory needs HPLC, a polarimeter, chiral HPLC, gas chromatography (GC), and a Karl Fischer instrument.

Levamisole operating costs mainly depend on raw materials, losses of the resolving agent, solvents, and labor. Thionyl chloride, caustic soda, and hydrochloric acid add to regular production costs. Energy is mainly used for solvent recovery, drying, cooling, and scrubber operation. Fixed costs include equipment depreciation, scrubbers, wastewater treatment, and quality control systems. In China, environmental compliance adds a significant share to fixed costs. Producing large volumes and fully recycling the D isomer helps reduce the cost per kilogram. Longer production runs also reduce the time and cost spent on equipment changeovers, cleaning, and testing.

Plant Location and Investment Factors

A suitable site for a levamisole plant is in a Chinese or Indian fine chemical industrial area with easy access to styrene oxide and the resolving agent. In China, Jiangsu province, especially around Changzhou and Nanjing, is home to leading producers. Zhejiang and Shandong have suppliers of chemical intermediates and solvent recovery services. Industrial areas in Gujarat and Hyderabad are suitable for Indian plants supplying veterinary medicine manufacturers for export. A suitable site needs acid gas scrubbers, systems to treat sulfur-containing waste, trained chemists, and the required environmental permits.

For a levamisole project, the first investment decision is backward integration into tetramisole. Buying racemate cuts capital, while making it lowers cost per kilogram and secures supply of the key intermediate. The second decision is grade, from veterinary to human pharmacopoeial. Veterinary API needs less paperwork, while human pharmacopoeial grade earns more. Product range is the third decision, and veterinary portfolios suit it best. Levamisole fits well with other veterinary APIs, such as albendazole, oxfendazole, and closantel. Strong customer controls are also needed because of diversion risk. These add cost but protect the license.

Major Levamisole Producing Regions

China is the largest levamisole source, with Changzhou Pharmaceutical, Nanjing White Whale Pharmaceutical & Changzhou Comwin Fine Chemicals among listed producers. Europe hosts distributors such as Chr. Olesen and veterinary formulators such as Norbrook. India produces veterinary API and finished products for South Asia, Africa & the Middle East, often at very low prices. Australia and New Zealand formulate large volumes of sheep and cattle drenches. Latin America, with Brazil and Argentina in the lead, is a major market for cattle wormers. Belgium holds the original Janssen research legacy. Little production remains there today.

Key Levamisole Producers

Changzhou Pharmaceutical Factory

• Chinese API maker based in Changzhou, Jiangsu province.
• Holds a CEP for levamisole hydrochloride, with a Eurofins audit report listed on Pharmaoffer.
• Competes on Chinese cost base, European compliance & broad API portfolio.
• Supplies human and veterinary formulators worldwide.

Nanjing White Whale Pharmaceutical

• Chinese API maker based in Nanjing, Jiangsu province.
• Holds a CEP for levamisole hydrochloride.
• Competes on focused anthelmintic production & regulated market filings.
• Serves European and other export markets.

Changzhou Comwin Fine Chemicals

• Chinese fine chemical and API maker in Changzhou.
• Listed as a GMP producer of levamisole hydrochloride.
• Competes on cost, intermediate access & flexible batch sizes.
• Serves veterinary and pharmaceutical customers.

Chr. Olesen

• Danish pharmaceutical ingredient distributor based in Copenhagen.
• Supplies levamisole hydrochloride of Chinese origin with a US DMF.
• Competes on supplier qualification, regulatory paperwork & European logistics.
• Serves human and veterinary formulators.

Norbrook Laboratories

• Northern Ireland-based veterinary medicines maker.
• Markets Levacide 7.5% levamisole injection for cattle and sheep.
• Competes on veterinary formulation, farm market reach & licensed products.
• Labels a dose of 7.5 mg per kg with 28-day cattle and 15-day sheep meat withdrawal.

Janssen Pharmaceutica

• Belgian research company, part of Johnson & Johnson, that discovered tetramisole and levamisole.
• Marketed Ergamisol in the US until its withdrawal in 2000.
• Developed the classic tetramisole chemistry and the move to the pure L isomer.
• No longer a major levamisole supplier.